Accelerate your neuroscience programmes with high‑quality, decision‑driving electrophysiology supported by specialists with deep, long‑standing expertise across preclinical neurophysiology platforms.
We generate robust functional and mechanistic data that de‑risk targets, strengthen therapeutic hypotheses, and support confident progression through discovery and preclinical development. Our experience includes:
Alongside our experimental services, we provide specialist consultancy — from study design and assay selection to data interpretation and support in establishing or optimising new electrophysiology laboratories.
Whether you need bespoke assays, expert guidance, or deep mechanistic insight, Neurexpert delivers the neurophysiology expertise to move your projects forward.
In humans, the EEG is a non-invasive method to record electrical brain activity. EEG recording is used extensively for research and diagnostic purposes in a wide range of neurological and psychiatric conditions. Such recordings can show specific rhythmic activity that can be characteristic biomarkers of behavioural states or disease conditions.
At Neurexpert we can record rhythmic or oscillatory activity, such as gamma and theta oscillations, from the in vitro brain slice. This activity can be considered to model human EEG activity. This allows us to evaluate drug action in an in vitro system and relate this to brain activity that can be recorded from humans under different physiological and pathological conditions. This makes the recording of oscillatory activity in brain slices an important tool to translate from the laboratory to the clinical situation.
View the video to learn more about EEG recording and how the brain slice preparation can be used to model this activity for the purposes of drug discovery.
Group II metabotropic glutamate (mGlu) receptors have been investigated as potential targets for the treatment of schizophrenia. Activation of these receptors has been shown to have antipsychotic-like effects in preclinical models of schizophrenia. In early clinical trials the receptors showed promise in reducing symptoms of schizophrenia, particularly in patients who were not responsive to traditional antipsychotic medications.
Recently we demonstrated that phencyclidine (PCP), known to evoke certain schizophrenia-like symptoms in humans, altered neuronal synchrony observed in the in vitro brain slice preparation. This disruption of activity was attenuated by activiation of Group II mGlu receptors.
This work can be viewed here: https://www.sciencedirect.com/science/article/pii/S0091305723000199?via%3Dihub
+44 1392 949169
